Search

Case of annular pustular psoriasis/circinate erythematous psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus: possible association with CARD-14 mutation. De novo annular pustular psoriasis following mRNA COVID-19 vaccine COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. [Extracted from the article]

On immunohistochemistry, the vascular growth stained positive for SARS-CoV-2 spike glycoprotein and only slightly positive for SARS-CoV-2 nucleocapsid protein (Fig. Coronavirus disease 2019 (COVID-19)-associated skin manifestations are protean.1 Likewise, the spectrum of anti-Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) vaccine-induced cutaneous reactions is constantly expanding.2 Although cases of eruptive pseudoangiomatosis (EP) and eruptive cherry angiomas have already been reported, both after COVID-19 and anti-SARS-CoV-2 vaccination,3 current evidence concerning SARS-CoV-2 and cutaneous angioproliferative disorders is limited. Agirgol I et al i .5 described the appearance of diffuse cherry angioma-like lesions on the upper body of a middle-aged man, who had previously developed an erythematous, papulovesicular - and later livedoid - rash during mild COVID-19. [Extracted from the article]

The article offers information on a study related to the problems and pitfalls in differential diagnosis of multisystem non-Langerhans cell histiocytoses (MS-NLCH). Topics discussed include categories of MS-NLCH include foamy-cell NLCH, Reticulohistiocytoses, and Rosai-Dorfman disease; investigation of clinical, histopathological, ultrastructural and molecular features of patients in the study; and the patients developed progressive syndrome involving skin, bone and central nervous system.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Albeit, its pathogenesis, is multifactorial; HS is regarded as mainly auto-inflammatory in its origin.1 In particular, the high expression levels of interleukin (IL)-17A in the bloodstream2 and in lesional skin3,4 of patients with HS, allow us to consider secukinumab as a potential drug capable of arresting the inflammatory cascade that characterizes this complicated pathology. The HiSCR was achieved only by 10% of patients (3/31) at week 5, by 26% of patients (8/24) at week 16 and by 41 % of patients (7/17) at week 28. [Extracted from the article]

SAPHO syndrome, namely Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, is a rare autoinflammatory chronic disease presenting with non‐infectious inflammatory osteitis, sterile joint inflammation and skin manifestations, including palmoplantar pustulosis and severe acne. The case of a 15‐year‐old boy affected by SAPHO syndrome and hidradenitis suppurativa (HS) is presented and discussed. Coexistence of these two diseases may represent a therapeutic challenge and this case confirms literature data reporting the efficacy of the combination of methotrexate and adalimumab in SAPHO complicated by HS. [ABSTRACT FROM AUTHOR]

Porokeratosis encompass a group of acquired and familial, preneoplastic, keratinization disorders, clinically characterized by atrophic macules or patches with a peripheral keratotic rim, the cornoid lamella. Genetic background is recognized as crucial in its pathophysiology, while immunosuppression and ultraviolet radiation represent triggering factors. We report the case of a woman who developed disseminate superficial actinic porokeratosis following the intake of hydroxyurea for a polycythaemia vera. Clinical, dermoscopic and histopathology data are showed, and the role of drug as a second-hit mutation trigger is discussed., (© 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists.)

EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included. With a follow-up visit at 6 months after enrolment, each patient had at least 12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life, and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1 year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients., (© 2021 Wiley Periodicals LLC.)

Background: Histiocytoses are haematological disorders of bone marrow origin that share many biological and clinical features with haematological neoplasms. The association between histiocytoses of the cutaneous-group and myeloid malignancies is a poorly investigated topic of high biological and clinical impact., Methods: We performed a systematic review of the scientific literature, compliant with PRISMA guidelines, to unravel the clinical and pathological features of this intriguing association., Findings: We gathered and analysed 102 patients. Most were children with generalised cutaneous eruptions and displayed risk organ involvement (i.e. bone marrow, spleen, liver). Interestingly, all these features are uncommonly encountered in C-group histiocytosis not associated with haematological neoplasms., Conclusions: Our review shows that generalised eruptions and risk organ involvement in cutaneous-group histiocytosis should raise a suspicion for a concomitant myeloid neoplasm both in children and in adults and warrant further investigations. A rapid recognition of this association is required to start a prompt and effective therapeutic management given the aggressive behaviour of the associated myeloid neoplasm in most instances., (© 2020 The Australasian College of Dermatologists.)

Hidradenitis suppurativa (HS) is a debilitating skin disease presenting with nodules, abscesses, and fistulae preferentially in the main folds. Adalimumab is the only licensed biologic for moderate-to-severe HS. Ultrasound demonstrated good sensitivity to provide anatomic and functional information in HS; in particular assessing vascularization, related to inflammation, and fibrosis in HS lesions before and after adalimumab treatment with ultrasound and Color Doppler may integrate clinical evaluation with imaging. Patients with moderate-to-severe HS were enrolled in this observational prospective study. Clinical evaluation (according to Hurley classification and International Hidradenitis Suppurativa Severity Score System score) and ultrasound (according to US HS-PGA)/Color Doppler were performed at baseline and after 12 weeks of adalimumab. Ultrasound was used for assessing fibrosis and Color Doppler for vascularization. For each patient, the three most severe lesions among abscesses and fistulae were chosen for total 96 lesions. Thirty-two patients were included, 18 men (56%) and 14 women (44%) with mean age 41.2. Mean IHS4 was 22.4 at baseline and dropped to 14.7 at week 12. Based on US HS-PGA, 14 out of 32 patients fell down by one or more classes of severity. Interestingly, adalimumab led to overall decrease in vascularization, particularly in lesions with intense vascular flow, which were 78 (81.3%) at baseline and became only 25 (26.04%). Finally, marked increase in fibrosis was seen after adalimumab, notably in lesions without fibrosis, which were 81 (84.4%) at baseline and became 15 (15.6%). This study confirms the efficacy of adalimumab in HS and provides value for vascularization and fibrosis as important ultrasonographic tools integrating clinical scores., (© 2020 Wiley Periodicals LLC.)